Voyager Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Voyager Therapeutics

11/03/2025 21:01

Voyager Therapeutics Inc VYGR.OQ reported a quarterly adjusted loss of 59 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $1.25.  The mean expectation of twelve analysts for the quarter was for a loss of 37 cents per share. Wall Street expected results to range from -52 cents to -13 cents per share.

Revenue fell 93% to $6.28 million from a year ago; analysts expected $16.58 million.

Voyager Therapeutics Inc's reported EPS for the quarter was a loss of 59 cents​.

The company reported a quarterly loss of $34.49 million.

Voyager Therapeutics Inc shares had fallen by 26.5% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 1.9% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for Voyager Therapeutics Inc is $16.00

This summary was machine generated from LSEG data March 11 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.37
-0.59
Missed
Sep. 30 2024
-0.45
-0.16
Beat
Jun. 30 2024
-0.41
-0.18
Beat
Mar. 31 2024
-0.44
-0.20
Beat